Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease
Alimentary Pharmacology & Therapeutics · 2025-09 · 62 (5) · 472-482
DOI: 10.1111/apt.70295 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 27.07.2025. Verfasst von Mohammad Shehab und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer, University Hospital, Kuwait. Hauptthemen laut MEDLINE: Biological Products, Crohn Disease. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Background
Advances in medical management of Crohn's disease (CD) have transformed therapeutic goals. Clinical and endoscopic remission are important endpoints.
Aim
To compare the efficacy of different advanced therapies in patients with CD.
Methods
We performed a literature search up to January 2025. We included phase 3 randomised controlled trials (RCTs) against placebo or an active comparator. The primary endpoint was induction and maintenance of clinical remission (CD Activity Index [CDAI] < 150 points). Secondary endpoints included induction and maintenance of endoscopic remission (Simple Endoscopic Score for CD (SES‐CD) of ≤ 4 or CD Endoscopic Index of Severity (CDEIS) of ≤ 4). We performed network meta‐analysis (NMA) using the Frequentist method.
Results
We included 39 studies. Induction of clinical remission analysis showed that infliximab combination with azathioprine ranked highest (93.2%), followed by guselkumab (88.6%) and adalimumab (76.9%). Guselkumab was superior to most interventions in inducing clinical remission. In maintenance of clinical remission, combination of infliximab and azathioprine ranked highest (75.7%) followed by mirikizumab (71.8%) and guselkumab (71.5%). There was no statistically significant difference between therapies in maintaining clinical remission. In induction of endoscopic remission, upadacitinib (88.5%) ranked highest, followed by risankizumab (73.7%) and guselkumab (73.4%). Guselkumab (74%) ranked highest in maintaining endoscopic remission, followed by adalimumab (67%) and mirikizumab (64%).
Conclusion
Novel IL‐23 inhibitors (such as mirikizumab, risankizumab and guselkumab) and anti‐TNFs (such as infliximab and adalimumab) ranked high in the induction of clinical and endoscopic remission. This highlights the potential of novel advanced therapies for CD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer, University Hospital, Kuwait.
- Department of Medicine, College of Medicine and Health Sciences, Abdullah Al Salem University, Kuwait.
- Division of Gastroenterology and Hepatology, Department of Medicine, McGill University Health Center, Montreal, Canada.
- Department of Pharmacy Practice, Faculty of Pharmacy, Kuwait University, Jabriya, Kuwait.
- Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Canada.
- Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Mohammad Shehab, Christopher Ma, Neeraj Narula, Vipul Jairat, Miguel Regueiro
Zitieren
APA
Shehab, M., Alrashed, F., Alrashidi, A., Hassan, A., Ma, C., Narula, N., Jairat, V., Regueiro, M., & Bessissow, T. (2025). Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease. Alimentary Pharmacology & Therapeutics, 62(5), 472-482. https://doi.org/10.1111/apt.70295
Vancouver
Shehab M, Alrashed F, Alrashidi A, Hassan A, Ma C, Narula N, et al. Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease. Alimentary Pharmacology & Therapeutics. 2025;62(5):472-482. doi:10.1111/apt.70295
BibTeX
@article{Shehab2025,
author = {Shehab, Mohammad and Alrashed, Fatema and Alrashidi, Abdulrahman and Hassan, Amro and Ma, Christopher and Narula, Neeraj and Jairat, Vipul and Regueiro, Miguel and Bessissow, Talat},
title = {Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
volume = {62},
number = {5},
pages = {472--482},
doi = {10.1111/apt.70295}
}
EUVIMED